logo
logo
HomeAbout UsPlatformInsights
Test Item

Test Item

Published : Invalid Date

Contact Us

📍

Address

One Research Ct, Suite 450
Rockville, MD 20850

✉️

For General Inquiry

info@pienomial.com

Related Posts

Alligator Bioscience Presents Positive Biomarker Data for Mitazalimab in Pancreatic Cancer at ASCO 2025

23 May 2025

Alligator Bioscience Presents Positive Biomarker Data for Mitazalimab in Pancreatic Cancer at ASCO 2025

Alligator Bioscience announced the presentation of biomarker data from its OPTIMIZE-1 clinical trial at the 2025 ASCO An...

Actuate Therapeutics' Elraglusib Shows Promising Results in Metastatic Pancreatic Cancer

26 Aug 2025

Actuate Therapeutics' Elraglusib Shows Promising Results in Metastatic Pancreatic Cancer

Actuate Therapeutics announced positive Phase 2 results for elraglusib (elra) in combination with gemcitabine and nab-pa...

AbbVie Announces Positive Phase 3 Results for Upadacitinib (RINVOQ®) in Vitiligo

30 Oct 2025

AbbVie Announces Positive Phase 3 Results for Upadacitinib (RINVOQ®) in Vitiligo

AbbVie announced positive topline results from two replicate Phase 3 studies evaluating upadacitinib (RINVOQ®) in adult ...

Alafair Biosciences Initiates Multi-Center Study on VersaWrap® for Achilles Tendon Repair

25 Jun 2025

Alafair Biosciences Initiates Multi-Center Study on VersaWrap® for Achilles Tendon Repair

Alafair Biosciences announced the enrollment of the first patient in a multi-center study evaluating VersaWrap®, a biore...

Aicuris' Pritelivir Meets Primary Endpoint in Phase 3 Trial for Refractory Herpes Simplex Virus in Immunocompromised Patients

16 Oct 2025

Aicuris' Pritelivir Meets Primary Endpoint in Phase 3 Trial for Refractory Herpes Simplex Virus in Immunocompromised Patients

Aicuris Anti-infective Cures AG announced positive results from its Phase 3 trial (PRIOH-1) of pritelivir for treating r...

Abivax Announces Positive Results from ABTECT Induction Trials of Obefazimod in Ulcerative Colitis Patients

06 Oct 2025

Abivax Announces Positive Results from ABTECT Induction Trials of Obefazimod in Ulcerative Colitis Patients

Abivax announced late-breaking presentation of 8-Week ABTECT Induction Trial results in participants with and without pr...

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

01 Sept 2025

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

Alnylam Pharmaceuticals announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) for zilebesiran, an i...

4TEEN4 Announces Promising First-in-Human Data for Procizumab in Cardiogenic Shock

15 Jul 2025

4TEEN4 Announces Promising First-in-Human Data for Procizumab in Cardiogenic Shock

4TEEN4 Pharmaceuticals announced the publication of data in the European Journal of Heart Failure demonstrating the effi...

Adagene Announces Positive Updated Data for Muzastotug (ADG126) in Combination with Pembrolizumab for Colorectal Cancer at ASCO

23 May 2025

Adagene Announces Positive Updated Data for Muzastotug (ADG126) in Combination with Pembrolizumab for Colorectal Cancer at ASCO

Adagene announced updated Phase 1b/2 data for its anti-CTLA-4 antibody, Muzastotug (ADG126), in combination with pembrol...

AbbVie's VERONA Trial for Higher-Risk Myelodysplastic Syndromes Misses Primary Endpoint

17 Jun 2025

AbbVie's VERONA Trial for Higher-Risk Myelodysplastic Syndromes Misses Primary Endpoint

AbbVie announced that the Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine for newly diagnosed...

AL-S Pharma Announces Positive Phase 2 Results for AP-101 in ALS Treatment

04 Sept 2025

AL-S Pharma Announces Positive Phase 2 Results for AP-101 in ALS Treatment

AL-S Pharma reported positive topline results from its Phase 2 clinical trial of AP-101, a first-in-class monoclonal ant...

Airiver Medical Receives FDA IDE Approval for Pivotal Clinical Study of Airiver Pulmonary Drug Coated Balloon

28 Aug 2025

Airiver Medical Receives FDA IDE Approval for Pivotal Clinical Study of Airiver Pulmonary Drug Coated Balloon

Airiver Medical announced that it has received Investigational Device Exemption (IDE) approval from the FDA to conduct a...

Abivax Announces Positive Phase 3 Results for Obefazimod in Ulcerative Colitis

23 Jul 2025

Abivax Announces Positive Phase 3 Results for Obefazimod in Ulcerative Colitis

Abivax announced positive topline results from its Phase 3 ABTECT-1 and ABTECT-2 trials evaluating obefazimod, a first-i...

Aldeyra Therapeutics Receives FDA Special Protocol Assessment for ADX-2191 in Primary Vitreoretinal Lymphoma

26 Jun 2025

Aldeyra Therapeutics Receives FDA Special Protocol Assessment for ADX-2191 in Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics announced that it received a Special Protocol Assessment Agreement from the FDA for ADX-2191, a nov...

Abbott's FreeStyle Libre CGM Reduces Cardiovascular Hospitalizations in People with Diabetes

16 May 2025

Abbott's FreeStyle Libre CGM Reduces Cardiovascular Hospitalizations in People with Diabetes

New data from Abbott's REFLECT real-world studies show that using FreeStyle Libre continuous glucose monitoring (CGM) te...

Actuate Therapeutics Announces Positive Phase 2 Elraglusib Data in Metastatic Pancreatic Cancer

23 May 2025

Actuate Therapeutics Announces Positive Phase 2 Elraglusib Data in Metastatic Pancreatic Cancer

Actuate Therapeutics announced positive topline Phase 2 data for elraglusib in combination with gemcitabine/nab-paclitax...

4B Technologies Announces Positive Phase 1 Results for Novel Non-Opioid Chronic Pain Therapy

18 Jul 2025

4B Technologies Announces Positive Phase 1 Results for Novel Non-Opioid Chronic Pain Therapy

4B Technologies announced positive topline results from a Phase 1 study of 4B03-04, a humanized monoclonal antibody for ...

AB Science Announces Initial Phase 1 Data for AB8939 and Venetoclax Combination in Refractory or Relapsed Acute Myeloid Leukemia

17 Oct 2025

AB Science Announces Initial Phase 1 Data for AB8939 and Venetoclax Combination in Refractory or Relapsed Acute Myeloid Leukemia

AB Science SA announced initial Phase 1 data for the combination of AB8939 with venetoclax for treating refractory or re...

AbCellera Announces Positive Preclinical Data for ABCL575, an Anti-OX40L Antibody for Atopic Dermatitis

12 May 2025

AbCellera Announces Positive Preclinical Data for ABCL575, an Anti-OX40L Antibody for Atopic Dermatitis

AbCellera presented preclinical data on ABCL575, a half-life extended anti-OX40L monoclonal antibody for moderate-to-sev...

Akebia Initiates Post-Marketing Study for Vafseo® (vadadustat) in CKD Anemia

05 Aug 2025

Akebia Initiates Post-Marketing Study for Vafseo® (vadadustat) in CKD Anemia

Akebia Therapeutics announced the initiation of VOCAL, a post-marketing study evaluating the efficacy and safety of Vafs...